ACLX
Company Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.29M | 107.94M | 110.32M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (228.93M) | (107.35M) | (70.69M) | (188.68M) | (64.97M) | (32.09M) | (17.97M) | (8.31M) |
| EPS | -4.07 | -2.00 | -1.47 | -4.28 | -1.94 | -1.47 | -0.52 | -50.17 |
| Free Cash Flow | (212.59M) | (96.90M) | 186.15M | (101.58M) | (60.02M) | (29.55M) | (22.60M) | (7.34M) |
| FCF / Share | -3.78 | -1.81 | 3.87 | -2.30 | -1.79 | -1.36 | -0.65 | -44.33 |
| Operating CF | (210.26M) | (83.47M) | 207.57M | (99.30M) | (54.24M) | (28.66M) | (18.77M) | (6.86M) |
| Total Assets | 603.99M | 711.33M | 825.13M | 313.82M | 128.78M | 57.69M | 43.59M | 15.81M |
| Total Debt | 96.26M | 54.08M | 97.62M | 88.13M | 0 | 0 | 0 | 0 |
| Cash & Equiv | 80.26M | 105.68M | 394.58M | 64.18M | 30.83M | 46.60M | 34.58M | 14.53M |
| Book Value | 402.35M | 454.79M | 485.38M | 204.95M | (121.52M) | 50.54M | (32.74M) | 13.96M |
| Return on Equity | -0.57 | -0.24 | -0.15 | -0.92 | N/A | -0.64 | N/A | -0.60 |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.65M | 4.95M | 7.55M | 8.13M | 15.27M | 26.03M | 27.38M | 39.26M | 63.15M | 14.96M | 14.30M | 17.91M |
| Net Income | (58.11M) | (55.78M) | (52.77M) | (62.27M) | (47.08M) | (25.87M) | (27.20M) | (7.20M) | 19.84M | (39.34M) | (23.85M) | (27.34M) |
| EPS | -1.01 | -0.99 | -0.94 | -1.13 | -0.88 | -0.48 | -0.51 | -0.14 | 0.38 | -0.81 | -0.50 | -0.58 |
| Free Cash Flow | (58.94M) | (49.50M) | (40.22M) | (63.92M) | (47.53M) | 28.43M | (39.46M) | (38.34M) | 52.95M | (18.03M) | (29.84M) | 181.06M |
| FCF / Share | -1.05 | -0.87 | -0.72 | -1.16 | -0.89 | 0.53 | -0.74 | -0.73 | 1.01 | -0.37 | -0.62 | 3.87 |
| Operating CF | (58.17M) | (49.21M) | (39.73M) | (63.15M) | (46.03M) | 30.72M | (36.25M) | (31.91M) | 58.25M | (10.10M) | (22.61M) | 182.04M |
| Total Assets | 603.99M | 655.92M | 619.09M | 648.08M | 711.33M | 764.91M | 734.31M | 779.70M | 825.13M | 614.22M | 623.53M | 622.94M |
| Total Debt | 96.26M | 51.79M | 52.51M | 53.19M | 54.08M | 65.33M | 74.29M | 87.36M | 97.62M | 108.72M | 93.64M | 87.65M |
| Cash & Equiv | 80.26M | 79.00M | 62.34M | 80.86M | 105.68M | 161.85M | 100.03M | 154.57M | 394.58M | 126.12M | 303.67M | 274.89M |
| Book Value | 402.35M | 440.78M | 392.22M | 416.91M | 454.79M | 483.02M | 487.16M | 496.57M | 485.38M | 266.13M | 293.67M | 303.72M |
| Return on Equity | -0.14 | -0.13 | -0.13 | -0.15 | -0.10 | -0.05 | -0.06 | -0.01 | 0.04 | -0.15 | -0.08 | -0.09 |
